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The extended spectrum -lactamase (ESBL) production and multidrug resistant of Klebsiella 
pneumoniae in children below 5 years of ages are investigated. The K. pneumoniae strains isolated 
from patients suffering from intestinal and extra intestinal infection between the 0 - 5 year’s ages of 
children showed resistant to the three antibiotics (ceftazidime, cefotaxime, ceftriaxone), and coexist 
with non -lactam resistance and ESBL production. All the strains were susceptibility to the antibiotic, 
imipenem. Out off 110 strains only 9 strains produced ESBL. The plasmid responsible for the antibiotic 
resistance and ESBL production can be transferred to recipient Escherichia coli strain. 
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INTRODUCTION   
 
Klebsiella pneumoniae is a successful opportunistic pa-
thogen and has been associated with various ailments 
such as urinary tract infection, septicemia, respiratory 
tract infection and diarrhea (Podschu and Ullmann, 
1998). In 1983, Extended Spectrum -Lactamase (ESBL) 
was found to confer resistance to broad spectrum cepha-
losporin (Knoth, 1983). Since then the promising and 
usable spectrum of third generation cephalosporin (3GC) 
like cefotaxime, ceftriaxone and ceftazidime, in the 
treatment of multidrug resistant K. pneumoniae infection 
has been limited as resistant strain have been reported 
(Brun-Buisson et al., 1987; Jarlier et al, 1988; Legakis et 
al., 1995; Abigail et al., 1995, Hobson et al., 1996, Subha 
et al., 2003, Abdul Rahaman and Kumar, 2005). The 
ESBL are mediated by plasmids which encode enzymes 
that hydrolyze the oxyimino--lactams and monobactams 
(Aztreonam) but have no effect on cephamycins (cefoxitin 
and cefotetan), carbapenems (imipenem) and related 
compounds (Philippon et al., 1989). Most ESBL are mu-
tant forms of sulphyl variable (SHV) enzymes coded by 
genes located on plasmid that can be easily spread from 
one organism to another (Sirot, 1995). These enzymes 
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(Rice, 1999). plasmid that can be easily spread from one 
organisms to another (Sirot, 1995) these enzymes are 
capable of inactivating a variety of -lactam drugs (Rice, 
1999). The ESBL producing organisms often show multi-
drug resistant as the plasmid carry resistance to 
antibiotics (Paterson, 1997; Steward, 2001). The increas-
ing antimicrobial resistance among ESBL producing 
bacteria makes therapy very difficult and leads to the use 
of expensive broad spectrum drugs, such as carbanpe-
nems, which are known to be most effective antibiotics 
against these organisms (Livermore, 1998).  
Children of less than five years of age group are very 
susceptible to intestinal and extra intestinal infections. In 
this study the ESBL prevalence and antimicrobial 
susceptibility of K. pneumoniae among the children under 
the 0 - 5 year’s ages was investigated.  
 
 




The clinical samples including blood, urine, stool and sputum are 
collected from the patient aged 0 - 5 years, at Government Hospital 
and Medical College, Anantapur, Andhra Pradesh, India, from the 
month of April 2005 to March 2006. The pathogenic microorganism 
K. pneumoniae was isolated and identified based on the colony 
morphology and biochemical reactions (Koneman  et al., 1992) and 
microbial populations were counted. The E. coli ATCC (25922) and  




Table 1. ESBL producing Klebsiella Pneumoniae isolates (110) and in their susceptibility categories by disc diffusion method. 
  
No. (%) of ESBL producing isolates with in each category with 30 mg disc of antibiotic Susceptibility 
category Aztreonam Cefotaxime Ceftazidime Cefoxitin 
Susceptible 18 (16.3) 17 (15.4) 19 (17.3) 79 (71.8) 
Intermediately resistant 15 (13.6) 54 (49) 25 (22.7) 8 (7.3) 















Double disc approximation test   
 
ESBL production was carried out by double disc approximation test 
(Jarlier et al., 1988). The strains were pre-incubated in brain heart 
infusion broth (BHIB) at 37oC and the optimal density of 0.5. This 
bacterial suspension was swabbed with sterile cotton on to a 
Mueller- Hinton agar medium. The antagonistic tests were conduc-
ted with antibiotic discs of Amoxicillin/Clavulanic acid (20/10 mg) 
and cefotoxime (30 mg) were placed at a distance of 15 cm apart 
from each other and incubated. After incubation the antibiotic 




NCCLS confirmatory test   
 
The Antibiotic resistance bacterial strain was confirmed by NCCLS 
(2000) confirmatory test. While performing antibiotic testing cefta-
zidime (30 mg) and ceftazidime and clavulanic acid (30/10 mg) 
were placed on Mueller Hinton agar media and incubated. After 
incubation the zone of inhibition was measured by standards 





 The antibiototic resistant and ESBL mediating gene was trans-
ferred to recipient E. coli K12 strains. The transconjugates were 
selected on Macon key agar containing antibiotics nalidixic acid 
(125 mg/ml) and cefotaxime (0.25 µg/ml) and identified biochemi-
cally by the method of Koneman et al. (1995). 
 
 
RESULTS AND DISCUSSION  
 
The antibiotic resistance pattern and activity of K. 
pneumoniae was detected and shown in the Table 1 and 
Figure 1. Out off 110 isolates of K. pneumoniae, all are 
found to be resistant to 3rd generation antibiotics (3GC) 
and these isolates showed multidrug resistance. 88 
(80%) of the isolates showed resistance or decreased 
susceptibility to various 3GC antibiotics (ceftazidime, 
cefotaxime, ceftriaxone) and coexisted with other 
antibiotics (Figure 1.) According to Padmini (2004), 90% 
of K. pneumoniae strains showed resistance to the 3GC 
antibiotics. Jacoby (1999) also reported that a particular 
plasmid is responsible for drug resistance and ESBL 
production. All the isolates were found susceptibility to 
the antibiotic imipenem. The ESBL production against the 
antibiotics, ceftazidime, cefotaxime and ceftriaxone was 
detected in 9 strains of K. pneumoniae (6 from urine, 2 
from stool and 1 from sputum). The gene responsible for 
resistance to the 3GC antibiotics and ESBL production 
was transferred to the recipient E. coli strain from 9 ESBL 
positive isolates. The Transconjugates were selected on 
Macon key agar containing the antibiotics nalidixic acid 
(125 mg/ml) and cefotaxime (0.25 µg/ml) and identified 
with the biochemical method of Koneman et al. (1995). 
Similar studies were made Jarlier et al. (1998).  
This study has revealed the occurrence of -lactamase 
producing strains of K. pneumoniae recovered from 
children with urinary tract infection, septicemia and 
respiratory tract infections. ESBL mediating resistance to 
3GC was found in 9% of isolates. The prevalence rate is 
higher than the reported figure of K. pneumoniae in 
Canada (6.2%) and United States of America (Jones et 
al., 1999) and lower in India (Padmini and Applaraju, 
2004). The incidence of ESBL producing strains among 
clinical Klebsiella isolates has steadily increased over the 
years and account for 6 to 17% of all nosocomial urinary 
tract infections. The detection rate of ESBL producing 
Klebsiella isolate in stool sample ranges from 5 to 38%. 
While rates in the nasophrynx range from 1 to 6%. In our 
study, isolates were obtained from stool (8.3%), urine 
(8.5%) and respiratory tract infection (16.6%). In addition 
to 3GC antibiotics, the isolates showed resistance to 
Amikacin (55%)  Tetracycline, (58%)  Co-trimoxozole 





The ESBL mediated and resistance gene was trans-
ferred to the recipient E. coli K 12 strain reported earlier 
(Jarlier et al., 1998). These plasmids are easily trans-
mitted among bacteria and this accounts for ESBL 
producing isolates that are resistance to a variety of 
antibiotics. According to Podschu and Ullmann (1998), 
the multidrug resistant Klebsiella strain is unfortunately 
accompanied by a relatively high stability of the plasmids. 
The present study has shown the incidence of multidrug 
resistant and ESBL producing Klebsiella isolates among 
children in Anantapur. Hence routine diagnosis should be 
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